Obstructive sleep apnea is a common and underdiagnosed condition in patients with type 2 diabetes. This blog post explores what is known about the underlying mechanism that may relate sleep apnea to diabetes.
- Posted November 19, 2013 by Doron Schneider, MD, FACP
- Posted May 29, 2013 by John L. Leahy, MD
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MD
- Posted May 30, 2012 by John L. Leahy, MDThe highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.
- Posted March 28, 2012 by John L. Leahy, MD
In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.
- Posted March 8, 2012 by Irl B. Hirsch, MDPrimary care physicians are expected to be experts on dozens of different disease states despite the fact that each medical problem continues to evolve, with new understanding of the disease itself and its treatments. Frankly, I see this as a near impossible task since as an endocrinologist I can barely keep up with diabetes (in reality I can’t).
- Posted February 22, 2012 by Doron Schneider, MD, FACPAlternative medicine (also known as complementary medicine) has become a multibillion dollar industry. A subset of complementary medicine is dietary supplements–many of which may hold promise as adjuncts to more traditional therapies and treatments. The evidence basis for many of these ”therapies,” however, often remains immature and at best anecdotal in nature.At the same time interest amongst the public and traditional healthcare providers has increased in recent years, as have formal studies with increasing scientific rigor led by the NIH and other prominent aca
- Posted July 20, 2011 by John L. Leahy, MD
A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability. Actually this is three topics. What are the specific mechanisms for the beta cell failure? Do any of our existing therapies, or those on the drawing board, reverse these mechanisms to slow or stop the beta cell failure?
- Posted August 1, 2010 by Kevin A. Peterson, MD, MPH
Do you recognize this patient? I have seen him in my office, or a person just like him. The Center for Disease Control (CDC, HHS) estimates that 57 million people in the U.S. have pre-diabetes. (1) If you look, you can probably recognize a person like this in every primary care office in the U.S. Unfortunately we still don’t have an evidence-based answer for the best therapeutic course for treatment of pre-diabetes.